TCA: Difference between revisions
CSV import |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 70: | Line 70: | ||
{{Psychopharmacology}} | {{Psychopharmacology}} | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
Latest revision as of 13:19, 18 March 2025
Tricyclic Antidepressants (TCA)
Tricyclic antidepressants (TCAs) are a class of medications that are primarily used to treat depression. They were first discovered in the early 1950s and were among the first antidepressants to be developed. TCAs are named for their chemical structure, which contains three rings of atoms.
Mechanism of Action[edit]
TCAs work by inhibiting the reuptake of neurotransmitters serotonin and norepinephrine in the brain, increasing their levels and prolonging their activity. This helps to improve mood and alleviate symptoms of depression. TCAs also affect other neurotransmitters, which can lead to a range of side effects.
Common TCAs[edit]
Some commonly prescribed TCAs include:
Uses[edit]
While primarily used to treat major depressive disorder, TCAs are also prescribed for other conditions, including:
- Anxiety disorders
- Chronic pain
- Migraine prophylaxis
- Obsessive-compulsive disorder (OCD)
- Enuresis (bedwetting) in children
Side Effects[edit]
TCAs can cause a variety of side effects due to their broad mechanism of action. Common side effects include:
- Dry mouth
- Constipation
- Urinary retention
- Blurred vision
- Drowsiness
- Weight gain
- Orthostatic hypotension
More serious side effects can include cardiac arrhythmias, especially in overdose situations, which can be life-threatening.
Contraindications[edit]
TCAs are contraindicated in patients with certain conditions, such as:
- Recent myocardial infarction
- Arrhythmias
- Severe liver disease
- Narrow-angle glaucoma
Interactions[edit]
TCAs can interact with a variety of other medications, including:
- Monoamine oxidase inhibitors (MAOIs)
- Selective serotonin reuptake inhibitors (SSRIs)
- Anticholinergic drugs
- Sympathomimetic drugs
History[edit]
The first TCA, imipramine, was discovered in the early 1950s by researchers at the Swiss pharmaceutical company Ciba-Geigy. It was initially developed as an antipsychotic but was found to have significant antidepressant effects. This discovery led to the development of other TCAs and the establishment of a new class of antidepressant medications.
Related Pages[edit]
- Selective serotonin reuptake inhibitor
- Monoamine oxidase inhibitor
- Serotonin-norepinephrine reuptake inhibitor
- Depression (mood)
- Anxiety disorder
- Chronic pain
- Migraine
- Obsessive-compulsive disorder
- Enuresis
